CRVS
Corvus Pharmaceuticals
Stock NASDAQ – Stock Market Prices, News & Analysis
Corvus Pharmaceuticals est une entreprise biopharmaceutique engagée dans le développement et la commercialisation de traitements immuno-oncologiques.
Corvus Pharmaceuticals
CRVS
Corvus Pharmaceuticals est une entreprise biopharmaceutique engagée dans le développement et la commercialisation de traitements immuno-oncologiques.
Price history of Corvus Pharmaceuticals
Price history of Corvus Pharmaceuticals
Performance & Momentum
Corvus Pharmaceuticals Shares Surge 212% on Trial Results
Corvus Pharmaceuticals (NASDAQ: CRVS) shares soared over 210% following positive clinical trial results for soquelitinib, a treatment for moderate to severe atopic dermatitis. These findings boost investor confidence in the drug's therapeutic potential, especially for patients resistant to existing treatments. Meanwhile, the company completed a $201 million capital raise to fund the launch of a Phase 2 trial, which is expected to support development and strengthen its position in the biopharmaceutical market.
Similar stocks to Corvus Pharmaceuticals
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
